ANZTCT consensus position statement on ruxolitinib in steroid‐refractory acute and chronic graft‐versus‐host disease-Reference-Cited by-同舟云学术

ANZTCT consensus position statement on ruxolitinib in steroid‐refractory acute and chronic graft‐versus‐host disease

Published:2023-11-28 Issue:12 Volume:53 Page:2319-2329
ISSN:1444-0903
Container-title:Internal Medicine Journal
language:en
Short-container-title:Internal Medicine Journal

Author:

Hamad Nada¹²³^ORCID,Bilmon Ian⁴,Chee Lynette⁵⁶,Henden Andrea⁷,Johnston Anna⁸,Purtill Duncan⁹¹⁰,Bajel Ashish⁵⁶,Tey Siok‐Keen⁷,Yeung David¹¹¹²,Cole Theresa¹³,Lewis Clinton¹⁴,Butler Jason⁷

Affiliation:

1. St Vincent's Hospital Sydney Sydney New South Wales Australia

2. School of Clinical Medicine UNSW Medicine & Health Sydney New South Wales Australia

3. School of Medicine Sydney University of Notre Dame Sydney New South Wales Australia

4. Westmead Hospital Sydney New South Wales Australia

5. Peter MacCallum Cancer Centre Melbourne Victoria Australia

6. Royal Melbourne Hospital Melbourne Victoria Australia

7. Royal Brisbane and Women's Hospital Brisbane Queensland Australia

8. Royal Hobart Hospital Hobart Tasmania Australia

9. Fiona Stanley Hospital Perth Western Australia Australia

10. PathWest Laboratory Medicine Perth Western Australia Australia

11. Royal Adelaide Hospital Adelaide South Australia Australia

12. South Australian Health and Medical Research Institute Adelaide South Australia Australia

13. Royal Children's Hospital Melbourne Victoria Australia

14. Auckland City Hospital Auckland New Zealand

Abstract

AbstractThis position paper provides an overview of the assessment and management of both acute and chronic graft‐versus‐host disease (GvHD). There is a focus on the use of ruxolitinib, a selective inhibitor of Janus kinase (JAK)1 and JAK2, for the treatment of corticosteroid‐refractory and corticosteroid‐dependent GvHD.

Funder

Novartis Australia

Publisher

Wiley

Subject

Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imj.16255

Reference37 articles.

1. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease

2. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

3. The improvement in overall survival from unrelated donor transplantation in Australia and New Zealand is driven by a reduction in non-relapse mortality: A study from the ABMTRR

4. Novartis Pharmaceuticals Australia Pty Limited.Australian Product Information – Jakavi (Ruxolitinib). 2022.

5. Novartis New Zealand Limited.Jakavi New Zealand Data Sheet.